preferenti local human adher lymphokine-activ killer cell tumor microcircul efficaci adopt immunotherapi solid tumor lymphokine-activ effector cell abil cell tumor tissu first quantit studi vivo movement adher lymphokine-activ killer a-lak cell cell low-dos normal matur granul tissu implant carcinoma grown rabbit ear chamber small proport a-lak cell tumor microcircul vivo increas frequenc long-term adhes interact tumor vasculatur stasi blood flow tumor vasculatur day inject subsequ necrosi tumor diffus infiltr lymphocyt monocyt granulocyt interstiti space tumor develop necrosi low ratio effector cell cell addit direct cytotox respons adopt immunotherapi tumor vasculatur novel mechan adopt immunotherapi account develop improv strategi cancer treatment 